Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. (NASDAQ: MDXG) is a regenerative medicine and advanced wound care company whose activities generate frequent news across clinical, regulatory, financial, and legal fronts. The company develops and markets placental tissue–based allografts and other biomaterial products used in chronic and hard-to-heal wounds, burn care, and selected surgical applications, and it regularly updates investors and clinicians on developments affecting these businesses.
News about MiMedx often includes announcements of new product launches and portfolio expansions, such as the introduction of EPIXPRESS, a lyophilized human placental-based allograft, and the exclusive U.S. distribution agreement for RegenKit Wound Gel. The company also highlights clinical and scientific milestones, including peer-reviewed publications on Purion processed human amniotic membrane allografts and interim results from randomized controlled trials like the CAMPAIGN study evaluating EPIEFFECT in nonhealing diabetic foot ulcers.
Investors following MDXG can expect regular earnings releases, conference call details, and commentary on reimbursement policy changes, particularly regarding Medicare rules for skin substitutes and advanced wound care products. MiMedx uses press releases to discuss how reimbursement reforms may affect its market and to describe its operational and commercial positioning.
In addition, MiMedx appears in news related to legal and regulatory matters, including litigation with former employees and references to FDA communications on specific products. Coverage may also include the company’s participation in investor conferences and clinical meetings such as the Symposium on Advanced Wound Care. For those tracking MDXG, this news stream provides insight into product performance, scientific evidence, regulatory context, and corporate strategy over time.
MIMEDX Group, Inc. (Nasdaq: MDXG) announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine to enhance scientific evidence supporting amniotic tissue therapies. This partnership aims to advance regenerative science and innovative biologics, with a focus on understanding product mechanisms and potential therapeutic targets. CEO Timothy R. Wright emphasized the importance of peer-reviewed data for patient care, while WFIRM's Dr. Anthony Atala expressed enthusiasm for the collaboration. MIMEDX continues to lead in amniotic tissue science and aims to develop next-generation therapies.
Prescience Point Capital Management has withdrawn its nominees for the MiMedx Group, Inc. (NASDAQ: MDXG) Board of Directors ahead of the Annual Meeting set for May 27, 2021. The firm believes its activism has led to significant improvements in corporate governance and a focus on enhancing shareholder value. Key governance proposals include lowering the special meeting ownership threshold from 50% to 25% and de-staggering the Board. Prescience Point remains a long-term stakeholder, emphasizing that MiMedx shares are undervalued, and encouraging shareholders to support the proposed changes.
MIMEDX Group, Inc. (NASDAQ: MDXG) urges shareholders to scrutinize Prescience Point's motives in its proxy fight for board influence. The Company highlights concerns over Prescience Point's trading practices, suggesting self-serving interests, and questions the qualifications of its nominees. MIMEDX emphasizes its turnaround success since appointing CEO Timothy R. Wright, noting a 237% increase in stock value and renewed credibility with the FDA. Shareholders are encouraged to vote for MIMEDX’s qualified directors at the upcoming Annual Meeting on May 27, 2021, to protect their investments.
MIMEDX Group, Inc. (NASDAQ: MDXG) urges shareholders to vote for its four director nominees at the virtual annual meeting on May 27, 2021. The company highlights a 237% stock price increase since CEO Timothy Wright's appointment in May 2019.
Key achievements under new management include the completion of five years of financial restatements, relisting on NASDAQ, resolution of litigation, and securing reimbursement coverage from major payors. MIMEDX aims to leverage opportunities in the regenerative medicine sector for sustainable growth and shareholder value.
MiMedx reported first quarter 2021 net sales of $60.0 million, a decrease from $61.7 million year-over-year. Adjusted net sales rose to $59.7 million from $57.2 million, driven by growth in the EpiFix® sheet portfolio. The net loss for the quarter was $8.4 million, compared to $4.8 million in Q1 2020. The company anticipates ongoing increases in research and development spending to support late-stage clinical trials, with significant data readouts expected in Q3 2021. MiMedx is committed to executing strategic initiatives to enhance stakeholder value amidst these developments.
MiMedx Group, Inc. (MDXG) has appointed Dirk Stevens, Ph.D., as Senior Vice President of Quality Assurance and Regulatory Affairs, effective May 3, 2021. Dr. Stevens brings over 35 years of experience in regulatory compliance from his previous role at Smith & Nephew, plc. CEO Timothy R. Wright stated that Stevens' expertise will enhance quality standards and support the advancement of MiMedx's late-stage pipeline. Dr. Stevens expressed enthusiasm about contributing to the company's mission in regenerative medicine, particularly in amniotic tissue biologics.
MiMedx Group, a leader in regenerative medicine utilizing amniotic tissue, will release its financial results for Q1 2021 after market close on April 28, 2021. A conference call and webcast will follow on April 29, 2021, at 8:30 AM ET, featuring CEO Timothy R. Wright and CFO Peter M. Carlson. MiMedx focuses on placental tissue allografts aimed at non-healing wounds and musculoskeletal conditions, having supplied over two million allografts. For more details, visit www.mimedx.com.
MiMedx Group, Inc. (NASDAQ: MDXG) announced the completion of patient visits for Phase 3 clinical trials of AmnioFix® Injectable, aimed at treating Plantar Fasciitis and Achilles Tendonitis. Additionally, the Phase 2B study for Knee Osteoarthritis has concluded. The company is now preparing for data analysis and plans to report top-line results in Q3 2021. MiMedx is also planning to submit a Biologics License Application (BLA) for Plantar Fasciitis in early 2022, while no BLA is anticipated for Achilles Tendonitis.
MiMedx Group, Inc. (NASDAQ: MDXG) announced that Prescience Point Capital Management has nominated four candidates for its Board of Directors ahead of the 2021 Annual Meeting on May 27, 2021. The current Board defends its leadership, highlighting a 148% stock price increase since the election of several board members in 2019. The management team asserts ongoing strategic initiatives to enhance shareholder value, despite Prescience Point's potential proxy contest. Shareholders are advised to await the definitive proxy statement for further details.
Prescience Point Capital Management, which holds about 8.1% of MiMedx Group's shares, has nominated four director candidates for the Board at the upcoming Annual Meeting on May 27, 2021. They assert that MiMedx is undervalued, primarily due to ineffective communication regarding its Amniofix product. The firm criticizes the current Board for concentrating power and failing to represent all shareholders' interests. Prescience Point believes that effective leadership is essential for realizing the Company's potential, particularly in relation to the growth opportunities presented by Amniofix.